Acadian Asset Management
OVID icon

Acadian Asset Management’s Ovid Therapeutics OVID Stock Holding History

Acadian Asset Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,231,698
Closed -$2.01M – 2196
2025
Q4 		$2.01M Sell
1,231,698
-1,054,807
-46% -$1.62M ﹤0.01% 911
2025
Q3 		$2.97M Buy
2,286,505
+178,169
+8% +$154K 0.01% 789
2025
Q2 		$693K Buy
2,108,336
+20,290
+1% +$6.11K ﹤0.01% 1067
2025
Q1 		$650K Buy
2,088,046
+237,445
+13% +$146K ﹤0.01% 1023
2024
Q4 		$1.73M Buy
1,850,601
+3,267
+0.2% +$3.66K 0.01% 801
2024
Q3 		$2.18M Buy
1,847,334
+182,782
+11% +$191K 0.01% 723
2024
Q2 		$1.28M Buy
1,664,552
+8,681
+0.5% +$24.2K ﹤0.01% 914
2024
Q1 		$5.05M Hold
1,655,871
– – 0.02% 465
2023
Q4 		$5.33M Sell
1,655,871
-45,357
-3% -$155K 0.02% 430
2023
Q3 		$6.53M Sell
1,701,228
-79,502
-4% -$286K 0.03% 362
2023
Q2 		$5.84M Sell
1,780,730
-143
-0% -$486 0.02% 413
2023
Q1 		$4.59M Sell
1,780,873
-33,689
-2% -$79.8K 0.02% 480
2022
Q4 		$3.37M Sell
1,814,562
-14,790
-0.8% -$25.2K 0.02% 547
2022
Q3 		$3.36M Sell
1,829,352
-122,111
-6% -$255K 0.02% 506
2022
Q2 		$4.2M Sell
1,951,463
-187,827
-9% -$454K 0.02% 456
2022
Q1 		$6.71M Buy
2,139,290
+99,206
+5% +$312K 0.03% 394
2021
Q4 		$6.54M Buy
2,040,084
+136,922
+7% +$469K 0.02% 403
2021
Q3 		$6.39M Buy
1,903,162
+64,916
+4% +$237K 0.02% 401
2021
Q2 		$7.19M Buy
1,838,246
+875,770
+91% +$3.46M 0.03% 381
2021
Q1 		$3.87M Buy
962,476
+609,818
+173% +$2.03M 0.02% 535
2020
Q4 		$815K Buy
+352,658
New +$1.64M ﹤0.01% 1051
2020
Q3 		– Sell
-4,164
Closed -$31K – 2310
2020
Q2 		$31K Sell
4,164
-91,574
-96% -$428K ﹤0.01% 2031
2020
Q1 		$285K Sell
95,738
-132,622
-58% -$447K ﹤0.01% 1111
2019
Q4 		$947K Sell
228,360
-4,378
-2% -$13.8K ﹤0.01% 890
2019
Q3 		$755K Buy
232,738
+21,248
+10% +$48.3K ﹤0.01% 975
2019
Q2 		$392K Buy
211,490
+57,592
+37% +$103K ﹤0.01% 1072
2019
Q1 		$272K Buy
153,898
+125,690
+446% +$314K ﹤0.01% 1276
2018
Q4 		$68K Hold
28,208
– – ﹤0.01% 1361
2018
Q3 		$160K Buy
28,208
+8,479
+43% +$64.3K ﹤0.01% 1111
2018
Q2 		$154K Buy
19,729
+12,294
+165% +$106K ﹤0.01% 1144
2018
Q1 		$52K Buy
+7,435
New +$60.2K ﹤0.01% 1347

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Acadian Asset Management's OVID Position: Q1 2026 in Review

Acadian Asset Management sold out of Ovid Therapeutics (OVID) in Q1 2026, closing a stake of 1,231,698 shares — an estimated $2.01M sold.

Acadian Asset Management first reported a position in OVID in Q1 2018 and held it in 31 quarters. The position peaked at $7.19M in Q2 2021. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Acadian Asset Management reported no remaining Ovid Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 1,231,698 Ovid Therapeutics shares in Q1 2026, an estimated $2.01M.
  • Acadian Asset Management first reported a position in Ovid Therapeutics in Q1 2018 and held it in 31 quarters.
  • Acadian Asset Management's Ovid Therapeutics position peaked at $7.19M in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.